Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on May 16, 2019, covering events occurring on May 15, 2019. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in High Point, NC. The report details an unregistered sale of equity securities under Item 3.02.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels. The specific financial event reported is a capital raise:
- Capital Raised: $2.5 million
- Shares Issued: 1,358,698 shares of Class A common stock
- Price Per Share: $1.84
- Investor: MacAndrews & Forbes Group LLC
Material Changes
The material change reported is the execution of a definitive agreement pursuant to a letter agreement dated December 11, 2018. The Company exercised its right to require the Investor to purchase the aforementioned shares. This transaction increased the Company's cash position by $2.5 million and diluted existing shareholders by the issuance of 1,358,698 new shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction is qualified by reference to the December 2018 Letter Agreement (Exhibit 10.24 to the 2019 Form 10-K). No unusual items or contingencies are described in this specific report.
Investor Verification Checklist
- Verify the terms of the December 2018 Letter Agreement referenced in the filing to understand the full scope of the investment relationship.
- Confirm the post-transaction share count and dilution impact on existing holdings.
- Review the Company's most recent Form 10-K (filed February 26, 2019) for baseline liquidity and cash burn rates prior to this capital infusion.
- Check for any subsequent filings regarding the use of the $2.5 million proceeds.